Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 8:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 37 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: ISS Clear all
Completed Phase 3 Interventional Results available

Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature

NCT01248416
View directory record Official record
Conditions
Idiopathic Short Stature
Interventions
Aromatase Inhibitor, Growth Hormone, Aromatase Inhibitor and Growth Hormone
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
12 Years to 18 Years · Male only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
3
States / cities
Jacksonville, Florida • Orlando, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 21, 2026, 8:26 AM EDT
Completed Phase 1 Interventional

Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers

NCT01401244
View directory record Official record
Conditions
Genetic Disorder, Prader-Willi Syndrome, Growth Disorder, Idiopathic Short Stature, Healthy
Interventions
somatropin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 40 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 24, 2017 · Synced Oct 21, 2026, 8:26 AM EDT
Completed No phase listed Observational

Pharmacodynamics of CNP During Growth Hormone Treatment

NCT01504802
View directory record Official record
Conditions
Pituitary Dwarfism, Idiopathic Short Stature
Interventions
Not listed
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
3 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Los Angeles, California • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 2, 2014 · Synced Oct 21, 2026, 8:26 AM EDT
Terminated Not applicable Interventional

Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window (ImpACT-24A)

NCT03767192
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Active Stimulation, Sham Stimulation
Device
Lead sponsor
BrainsGate
Industry
Eligibility
18 Years to 85 Years
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 28, 2019 · Synced Oct 21, 2026, 8:26 AM EDT
Terminated Phase 1 Interventional

A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer

NCT00403052
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
1018 ISS immunostimulatory oligonucleotide
Drug
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
3
States / cities
Santa Monica, California • Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 21, 2026, 8:26 AM EDT
Active, not recruiting Phase 2 Interventional

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

NCT05497804
View directory record Official record
Conditions
ISS Stage III Plasma Cell Myeloma, Multiple Myeloma
Interventions
Bone Marrow Aspiration and Biopsy, Carfilzomib, Computed Tomography, Daratumumab, Dexamethasone, Lenalidomide, Magnetic Resonance Imaging, Positron Emission Tomography, Multigated Acquisition Scan, Biospecimen Collection, Echocardiography, Chest Radiography
Procedure · Drug · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 21, 2026, 8:26 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Research Study Looking at How Safe Somapacitan is and How Well it Works in Children Who Need Help to Grow - REAL 9

NCT05723835
View directory record Official record
Conditions
SGA, Turner Syndrome, Noonan Syndrome, ISS
Interventions
Somapacitan
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
10 Years to 18 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Birmingham, Alabama • Sacramento, California • Centennial, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 21, 2026, 8:26 AM EDT
Not listed Phase 1 Interventional

NK Cells in Cord Blood Transplantation

NCT01619761
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, ISS Stage II Plasma Cell Myeloma, ISS Stage III Plasma Cell Myeloma, Myelodysplastic Syndrome, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Lenalidomide, Melphalan, Mycophenolate Mofetil, Natural Killer Cell Therapy, Rituximab, Tacrolimus, Total-Body Irradiation, Umbilical Cord Blood Transplantation
Procedure · Drug · Other + 2 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 75 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Oct 21, 2026, 8:26 AM EDT
Terminated Phase 2 Interventional Results available

rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency

NCT00572156
View directory record Official record
Conditions
Insulin-like Growth Factor-1 Deficiency
Interventions
NutropinAq® (Somatropin [rDNA origin]), Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])
Drug
Lead sponsor
Ipsen
Industry
Eligibility
5 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Brisbane, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Oct 21, 2026, 8:26 AM EDT
Recruiting No phase listed Observational

A Study to Assess Growth in Children With Idiopathic Short Stature

NCT06309979
View directory record Official record
Conditions
Idiopathic Short Stature
Interventions
Not listed
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
2 Years to 16 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2040
U.S. locations
38
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 21, 2026, 8:26 AM EDT
Completed Phase 1 Interventional

Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients

NCT00426712
View directory record Official record
Conditions
Hepatitis B
Interventions
1018 ISS immunostimulatory oligonucleotide with HBV surface antigen, Hepatitis B Vaccine (Recombinant)
Biological
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
40 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
4
States / cities
Costa Mesa, California • Brooklyn Center, Minnesota • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 21, 2026, 8:26 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Safety and Tolerability Study of Neural Stem Cells (NR1) in Subjects With Chronic Ischemic Subcortical Stroke (ISS)

NCT04631406
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Neural Stem Cells
Biological
Lead sponsor
Clarion Cells, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 21, 2026, 8:26 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Skeletal Muscle Effects of GH in Boys

NCT04020913
View directory record Official record
Conditions
Growth Hormone Deficiency, Idiopathic Short Stature
Interventions
Somatropin injection
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
6 Years to 11 Years · Male only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 21, 2026, 8:26 AM EDT
Recruiting Phase 3 Interventional

Comparison of Weekly Somatrogon to Daily Genotropin in Children Born Small for Gestational Age or With Idiopathic Short Stature.

NCT07226089
View directory record Official record
Conditions
ISS, SGA
Interventions
Somatrogon, Genotropin
Drug
Lead sponsor
Rabin Medical Center
Other
Eligibility
3 Years to 11 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
12
States / cities
Los Angeles, California • Centennial, Colorado • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 21, 2026, 8:26 AM EDT
Active, not recruiting Phase 3 Interventional

A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow

NCT05330325
View directory record Official record
Conditions
SGA, Turner Syndrome, Noonan Syndrome, ISS
Interventions
Somapacitan, Norditropin®
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
2 Years to 10 Years
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
35
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 21, 2026, 8:26 AM EDT
Completed Not applicable Interventional Results available

Investigating Superion™ In Spinal Stenosis

NCT00692276
View directory record Official record
Conditions
Lumbar Spinal Stenosis, Intermittent Claudication
Interventions
Superion™ Interspinous Spacer, X-STOP® IPD® Device
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
45 Years and older
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
32
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Oct 21, 2026, 8:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Pharmacokinetics, and Pharmacodynamics of SD-101 in Healthy Normal Males

NCT00599001
View directory record Official record
Conditions
Healthy
Interventions
SD-101, placebo
Drug
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 21, 2026, 8:26 AM EDT
Terminated No phase listed Observational

Study to Identify Markers of Insulin Resistance During Growth Hormone Treatment for Short Stature

NCT00121875
View directory record Official record
Conditions
Turner Syndrome, Idiopathic Short Stature
Interventions
somatropin (rDNA)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
7 Years to 14 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 29, 2009 · Synced Oct 21, 2026, 8:26 AM EDT
Completed Not applicable Interventional

Trialing of ISS in Patients With CRPS

NCT03954080
View directory record Official record
Conditions
CRPS I, Causalgia
Interventions
Intraspinal-optimal stim therapy
Device
Lead sponsor
Millennium Pain Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Bloomington, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 21, 2026, 8:26 AM EDT
Terminated No phase listed Observational

A Study of the Genetic Basis of Response to Growth Hormone Treatment in Children With Idiopathic Short Stature

NCT05894876
View directory record Official record
Conditions
Idiopathic Short Stature
Interventions
No treatment is given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
3 Years to 11 Years
Enrollment
43 participants
Timeline
2024 – 2025
U.S. locations
2
States / cities
Orange, California • Columbia, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 21, 2026, 8:26 AM EDT
Recruiting Phase 2 Interventional

A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature

NCT06382155
View directory record Official record
Conditions
Idiopathic Short Stature
Interventions
Vosoritide Injection, Human Growth Hormone, Placebo
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
3 Years to 11 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2036
U.S. locations
35
States / cities
California City, California • Los Angeles, California • Oakland, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 21, 2026, 8:26 AM EDT
Completed No phase listed Observational

Use of Non Invasive Hemodynamic Cardiovascular Monitoring to Evaluate Emergency Department Patients

NCT00851214
View directory record Official record
Conditions
COPD, Congestive Heart Failure, Trauma, Sepsis, Stroke
Interventions
NexfinHD Monitor
Device
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 18, 2010 · Synced Oct 21, 2026, 8:26 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma

NCT03267888
View directory record Official record
Conditions
ISS Stage I Plasma Cell Myeloma, ISS Stage II Plasma Cell Myeloma, ISS Stage III Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Pembrolizumab, Radiation Therapy
Biological · Radiation
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Oct 21, 2026, 8:26 AM EDT
Recruiting Phase 3 Interventional

Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders

NCT07221851
View directory record Official record
Conditions
Turner Syndrome, Short Stature Homeobox Gene Mutation, Idiopathic Short Stature, Small for Gestational Age at Delivery
Interventions
Lonapegsomatropin [SKYTROFA®], Somatropin Pen Injector
Combination Product
Lead sponsor
Ascendis Pharma A/S
Industry
Eligibility
2 Years to 17 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
23
States / cities
Palo Alto, California • Sacramento, California • Aurora, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 21, 2026, 8:26 AM EDT